IP Library Granted Patent US 8,791,078
Granted Patent B2
US 8,791,078 · App. 13/386,310 · Granted Jul 29, 2014

Cell protection in dialysis patients by administration of a creatine compound

Inventor: Ulrich Kirschner (Cologne, DE)
Assignee: Crearene Ltd.
A61K31/19A61K45/06A61K33/10A61K33/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,791,078
App. No.
13/386,310
Granted
Jul 29, 2014
Kind
B2
Abstract

The invention relates to a dialysis solution for haemodialysis or peritoneal dialysis, said solution having a theoretical osmolarity within the range of from 250 to 550 mosm/L and a pH value within the range of from 4.9 to 8.0, said solution comprising a creatine compound and one or more electrolytes, wherein the concentration of the creatine compound is not more than 50 mM.

Claims (35)

1. A dialysis solution for haemodialysis or peritoneal dialysis, said solution having a theoretical osmolarity within a range from 250 to 550 mosm/L and a pH value within a range from 4.9 to 8.0, said solution comprising a creatine compound and one or more electrolytes, wherein a concentration of the creatine compound is not more than 50 mM.

2. The dialysis solution according to claim 1 , wherein the concentration of the creatine compound is within the range from 0.001 to 2.5 mM.

3. The dialysis solution according to claim 1 , wherein the creatine compound is selected from the group consisting of creatine and physiologically acceptable salts thereof.

4. The dialysis solution according to claim 1 , which further comprises:

one or more non-ionic tonicity agents; and/or

one or more buffers.

5. The dialysis solution according to claim 4 , wherein said one or more electrolytes, said one or more non-ionic tonicity agents, and/or said one or more buffers are:

a) 1.0 to 250 mM glucose; and/or

b) 100 to 180 mM Na + ; and/or

c) 0.5 to 5.0 mM K + ; and/or

d) 0.5 to 2.0 mM Ca 2+ ; and/or

e) 0.25 to 1.50 mM Mg 2+ ; and/or

f) 75 to 130 mM Cl − ; and/or

g) 20 to 50 mM HCO 3 − ; and/or

h) 20 to 50 mM lactate; and/or

i) 2.0 to 7.5 mM acetate.

6. A kit configured for a preparation of the dialysis solution according to claim 1 comprising:

a) a first component composition;

b) a second component composition; and

c) optionally, one or more further component composition(s);

wherein the first component composition, the second component composition and the optionally one or more further component composition(s) are adapted to yield the dialysis solution according to claim 1 when being mixed with one another.

7. The kit according to claim 6 , which is a multi-chamber bag system containing the first component composition, the second component composition and the optionally one or more further component composition(s) in chambers separated from one another by breakable connecting arrangement(s), where the first component composition, the second component composition and the optionally one or more further component composition(s) can be mixed, following a breaking of the breakable connecting arrangement(s), thereby yielding the dialysis solution.

8. The kit according to claim 6 , wherein the first component composition is a sterilized solution containing a non-ionic tonicity agent and an acid and having a pH value below 6.0; wherein the second component composition is a sterilized solution containing a buffer and having a pH value above 7.0; wherein the first component composition and/or the second component composition and/or the optionally one or more further component composition(s) contain one or more electrolytes; and wherein the first component composition and/or the second component composition and/or the optionally one or more further component composition(s) contain the creatine compound.

9. The kit according to claim 6 , wherein the second component composition contains the total amount of the creatine compound.

10. A solid preparation adapted for the preparation of the dialysis solution according to claim 1 when being dissolved in a predefined volume of a liquid.

11. The solid preparation according to claim 10 , which contains a bicarbonate salt.

12. The solid preparation according to claim 11 , wherein a relative molar ratio of the bicarbonate salt to the creatine compound is within a range from 1:10 to 10:1.

13. The solid preparation according to claim 10 , wherein the predefined volume of a liquid is within a range from 1 to 2000 L.

14. The solid preparation according to claim 10 , wherein the liquid is purified water only or, optionally purified water containing one or more electrolytes and/or one or more non-ionic tonicity agents and/or one or more buffers.

15. The dialysis solution according to claim 1 , wherein the concentration of the creatine compound is not more than 30 mM.

16. The dialysis solution according to claim 1 , wherein the concentration of the creatine compound is not more than 20 mM.

17. The dialysis solution according to claim 1 , wherein the concentration of the creatine compound is not more than 10 mM.

18. The dialysis solution according to claim 1 , wherein the concentration of the creatine compound is not more than 5 mM.

19. The dialysis solution according to claim 5 , wherein the concentration of the creatine compound is within a range from 0.004 to 1.2 mM.

20. The dialysis solution according to claim 5 , wherein the concentration of the creatine compound is within a range from 0.8 to 1.2 mM.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2020
From: CREARENE LTD.
To: CREARENE AG
Reel/Frame 051666/0684 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2012
From: KIRSCHNER, ULRICH
To: CREARENE LTD.
Reel/Frame 027691/0587 →
Priority Claims (1)
EP 09009618 · Jul 24, 2009 · regional
Continuity (1)
Related Publication 20120135943A1 · May 31, 2012